Cargando…

Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma

SIMPLE SUMMARY: For patients with metastatic melanoma, a rapid BRAF mutation assessment is vital to reveal the treatment options per patient. Additionally, close monitoring of the disease during treatment is essential to allow for adjustments in the treatment strategy when needed. The aim of this pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tolmeijer, Sofie H., Koornstra, Rutger H. T., de Groot, Jan Willem B., Geerlings, Maartje J., van Rens, Dirk H., Boers-Sonderen, Marye J., Schalken, Jack A., Gerritsen, Winald R., Ligtenberg, Marjolijn J. L., Mehra, Niven
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345527/ https://www.ncbi.nlm.nih.gov/pubmed/34359813 http://dx.doi.org/10.3390/cancers13153913

Ejemplares similares

Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity
por: van Wilpe, Sandra, et al.
Publicado: (2021)

Lactate dehydrogenase: a marker of diminished antitumor immunity
por: Van Wilpe, Sandra, et al.
Publicado: (2020)

Case series: indoor-photosensitivity caused by fluorescent lamps in patients treated with vemurafenib for metastatic melanoma
por: Boudewijns, Steve, et al.
Publicado: (2014)

Correction to: Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2022)

Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2021)

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination
por: van Willigen, Wouter W., et al.
Publicado: (2020)

Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer
por: van Wilpe, Sandra, et al.
Publicado: (2021)

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy
por: Bloemendal, Martine, et al.
Publicado: (2019)

Impact of DNA damage repair defects and aggressive variant features on response to carboplatin‐based chemotherapy in metastatic castration‐resistant prostate cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2020)

The Impact of Dose and Simultaneous Use of Acid-Reducing Agents on the Effectiveness of Vemurafenib in Metastatic BRAF V600 Mutated Melanoma: a Retrospective Cohort Study
por: Knapen, Lotte M., et al.
Publicado: (2018)

Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition
por: Tel, Jurjen, et al.
Publicado: (2016)

Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Circulating Tumor DNA-Based Disease Monitoring of Patients with Locally Advanced Esophageal Cancer
por: Hofste, Lisa S. M., et al.
Publicado: (2022)

Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer
por: Smits, Minke, et al.
Publicado: (2020)

A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery
por: Creemers, Jeroen H A, et al.
Publicado: (2021)

Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype
por: van Wilpe, Sandra, et al.
Publicado: (2022)

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
por: Schouwenburg, Maartje G., et al.
Publicado: (2019)

A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics
por: Lubberman, Floor J. E., et al.
Publicado: (2019)

Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223
por: van der Doelen, Maarten J., et al.
Publicado: (2021)

Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder
por: van Wilpe, Sandra, et al.
Publicado: (2020)

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
por: Boudewijns, Steve, et al.
Publicado: (2016)

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
por: Ismail, Rawa K., et al.
Publicado: (2022)

Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate Cancer
por: Slootbeek, Peter H. J., et al.
Publicado: (2023)

Serum S100B and LDH at Baseline and During Therapy Predict the Outcome of Metastatic Melanoma Patients Treated with BRAF Inhibitors
por: Gassenmaier, Maximilian, et al.
Publicado: (2021)

Adjuvant BRAF-MEK Inhibitors versus Anti PD-1 Therapy in Stage III Melanoma: A Propensity-Matched Outcome Analysis
por: De Meza, Melissa M., et al.
Publicado: (2023)

Immunological responses to adjuvant vaccination with combined CD1c(+) myeloid and plasmacytoid dendritic cells in stage III melanoma patients
por: Bloemendal, Martine, et al.
Publicado: (2021)

Current and Emerging Treatment Options for Castration-Resistant Prostate Cancer: A Focus on Immunotherapy
por: Gerritsen, Winald R., et al.
Publicado: (2011)

Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol
por: Creemers, Jeroen H A, et al.
Publicado: (2021)

High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
por: Westdorp, Harm, et al.
Publicado: (2020)

Special Issue: Layered Double Hydroxides (LDH) and LDH-Based Hybrid Composites
por: Matusik, Jakub
Publicado: (2021)

Clinical Validity of Tumor-Informed Circulating Tumor DNA Analysis in Patients Undergoing Surgery of Colorectal Metastases
por: Hofste, Lisa S.M., et al.
Publicado: (2022)

Validating lactate dehydrogenase (LDH) as a component of the PLASMIC predictive tool (PLASMIC-LDH)
por: Liam, Christopher Chin Keong, et al.
Publicado: (2023)

LDH-A—Modulation and the Variability of LDH Isoenzyme Profiles in Murine Gliomas: A Link with Metabolic and Growth Responses
por: Shindo, Masahiro, et al.
Publicado: (2022)

Glucocorticoids inhibit macrophage differentiation towards a pro-inflammatory phenotype upon wounding without affecting their migration
por: Xie, Yufei, et al.
Publicado: (2019)

Evaluation of the rapid diagnostic test CareStart pLDH Malaria (Pf-pLDH/pan-pLDH) for the diagnosis of malaria in a reference setting
por: Heutmekers, Marloes, et al.
Publicado: (2012)

Systematic search of Bayesian statistics in the field of psychotraumatology
por: van de Schoot, Rens, et al.
Publicado: (2017)

Pharmacokinetic Aspects of the Two Novel Oral Drugs Used for Metastatic Castration-Resistant Prostate Cancer: Abiraterone Acetate and Enzalutamide
por: Benoist, Guillemette E., et al.
Publicado: (2016)

Increased LDH5/LDH1 ratio in preoperative diagnosis of uterine sarcoma with inconclusive MRI and LDH total activity but suggestive CT scan: a case report
por: Mollo, Antonio, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nnikbaomshr54ce03ek2c94af1